Inj pembrolizumab
Products billed under this code include Keytruda.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Keytruda.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Keytruda | Merck Sharp & Dohme LLC | 00006-3026-02 | 100 | $6,225.30 |
| Keytruda | Merck Sharp & Dohme LLC | 00006-3026-04 | 200 | $12,450.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $62.253 | +$1.608 | 1 MG | Inj pembrolizumab | v1, posted September 17, 2026 |
| 3Q26 | $60.645 | −$0.606 | 1 MG | Inj pembrolizumab | v1, posted September 15, 2026 |
| 2Q26 | $61.251 | +$1.525 | 1 MG | Inj pembrolizumab | v1, posted September 15, 2026 |
| 1Q26 | $59.726 | −$0.565 | 1 MG | Inj pembrolizumab | v1, posted September 15, 2026 |
| 4Q25 | $60.291 | +$1.729 | 1 MG | Inj pembrolizumab | v1, posted September 8, 2026 |
| 3Q25 | $58.562 | −$0.787 | 1 MG | Inj pembrolizumab | v1, posted March 10, 2026 |
| 2Q25 | $59.349 | +$1.746 | 1 MG | Inj pembrolizumab | v1, posted March 10, 2026 |
| 1Q25 | $57.603 | −$0.613 | 1 MG | Inj pembrolizumab | v1, posted December 19, 2025 |
| 4Q24 | $58.216 | +$1.558 | 1 MG | Inj pembrolizumab | v1, posted June 11, 2025 |
| 3Q24 | $56.658 | −$0.649 | 1 MG | Inj pembrolizumab | v1, posted June 11, 2025 |
| 2Q24 | $57.307 | +$1.577 | 1 MG | Inj pembrolizumab | v1, posted March 11, 2025 |
| 1Q24 | $55.73 | −$0.682 | 1 MG | Inj pembrolizumab | v1, posted December 19, 2024 |
| 4Q23 | $56.412 | +$1.601 | 1 MG | Inj pembrolizumab | v1, posted October 10, 2024 |
| 3Q23 | $54.811 | −$0.606 | 1 MG | Inj pembrolizumab | v1, posted June 5, 2024 |
| 2Q23 | $55.417 | +$1.503 | 1 MG | Inj pembrolizumab | v1, posted February 23, 2024 |
| 1Q23 | $53.914 | −$0.634 | 1 MG | Inj pembrolizumab | v1, posted December 6, 2023 |
| 4Q22 | $54.548 | +$1.409 | 1 MG | Inj pembrolizumab | v1, posted June 22, 2023 |
| 3Q22 | $53.139 | −$0.56 | 1 MG | Inj pembrolizumab | v1, posted June 9, 2023 |
| 2Q22 | $53.699 | +$1.399 | 1 MG | Inj pembrolizumab | v1, posted December 14, 2022 |
| 1Q22 | $52.30 | −$0.454 | 1 MG | Inj pembrolizumab | v1, posted June 8, 2022 |
| 4Q21 | $52.754 | +$1.405 | 1 MG | Inj pembrolizumab | v1, posted June 2, 2022 |
| 3Q21 | $51.349 | −$0.267 | 1 MG | Inj pembrolizumab | v1, posted June 2, 2022 |
| 2Q21 | $51.616 | +$0.968 | 1 MG | Inj pembrolizumab | v1, posted March 1, 2022 |
| 1Q21 | $50.648 | – | 1 MG | Inj pembrolizumab | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.